

Canada

Hospitals

[Edmonton.](#)

[Halifax.](#)

[Hamilton.](#)

[Montreal.](#)

[Toronto.](#)

[Vancouver.](#)

[Winnipeg.](#)

Residency

see [Residency in Canada.](#)

Training

Staudt MD. Neurosurgical Training in Canada: Changing Landscape with Ongoing Challenges. World Neurosurg. 2019 Aug 20;132:26-28. doi: 10.1016/j.wneu.2019.08.080. [Epub ahead of print] PubMed PMID: 31541975.

Neuromodulation in Canada

Lipsman N, McDonald P. Charting the Neuroethics Landscape for [Neuromodulation](#) in Canada and Beyond. Can J Neurol Sci. 2023 Jun;50(s1):s2-s3. doi: 10.1017/cjn.2022.294. Epub 2023 May 10. PMID: 37160679.

Spinal Cord Injury

The Rick Hansen Spinal Cord Injury Registry (RHSCIR) is a national SCI Registry that enters SCI patients from acute-care centers across [Canada](#).

To predict the feasibility of conducting clinical trials of acute SCI within Canada, Thibault-Halman et al., have applied the inclusion/exclusion criteria of six previously conducted SCI trials to the RHSCIR dataset and generated estimates of how many Canadian individuals would theoretically have been eligible for enrollment in these studies. Data for SCI cases were prospectively collected for RHSCIR at

18 acute and 13 rehabilitation sites across Canada. RHSCIR cases enrolled between 2009-2013 who met the following key criteria were included: non-penetrating traumatic SCI; received acute care at a RHSCIR site; age >18- <75 years, and had complete admission single neurological level of injury data. Inclusion and exclusion criteria for the [Minocycline](#) in Acute Spinal Cord injury (Minocycline), Riluzole, Surgical Timing in Acute Spinal Cord Injury Study (STASCIS), Cethrin, Nogo antibody study (NOGO) and Sygen studies were applied retrospectively to this dataset. The numbers of patients eligible for each clinical trial were determined. 2166 of the initial 2714 cases (79.8%) met the key criteria and were included in the dataset. Projected annual numbers of eligible patients for each trial was: Minocycline 117 cases; Riluzole 62 cases; STASCIS 109 cases; Cethrin 101 cases; NOGO 82 cases; and Sygen 70 cases. An additional 8.0% of the sample had a major head injury (GCS \leq 12) and would have been excluded from the trials. RHSCIR provides a comprehensive national dataset which may serve as a useful tool in the planning of multicentre clinical SCI trials ¹⁾.

Canadian Consortium on Neurodegeneration in Aging

[Canadian Consortium on Neurodegeneration in Aging](#)

¹⁾

Thibault-Halman G, Rivers CS, Bailey C, Tsai E, Drew B, Noonan V, Fehlings M, Dvorak MF, Kuerban D, Kwon BK, Christie S. Predicting recruitment feasibility for acute spinal cord injury clinical trials in Canada using national registry data. J Neurotrauma. 2016 Sep 14. [Epub ahead of print] PubMed PMID: 27627704.

From:

<https://neurosurgerywiki.com/wiki/> - **Neurosurgery Wiki**

Permanent link:

<https://neurosurgerywiki.com/wiki/doku.php?id=canada>

Last update: **2024/06/07 02:57**

